Skip to main content
NVDA-1.38%AAPL+0.39%GOOGL-2.28%MSFT-0.70%AMZN-0.68%TSM-0.83%SPCX-3.86%AVGO-1.13%META-0.31%TSLA-2.02%SKHY+7.05%MU-2.75%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.71%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-2.36%0005.HK-0.78%HSBA.L-1.48%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.41%AUDJPY-1.70%CHFJPY-1.62%NZDCAD-1.32%EURJPY-1.26%NZDUSD-1.26%GBPJPY-1.25%EURNZD+1.20%USDJPY-1.18%GBPNZD+1.17%CADJPY-1.10%USDZAR+0.84%NZDCHF-0.82%USDNOK+0.79%AUDNZD+0.74%USDSEK+0.70%AUDCAD-0.62%USDTHB+0.61%EURZAR+0.60%EURNOK+0.54%GBPZAR+0.54%AUDUSD-0.51%CADCHF+0.50%USDPLN+0.49%AUDSGD-0.48%USDMXN+0.48%AUDDKK-0.47%EURSEK+0.46%USDCHF+0.46%EURAUD+0.45%GBPAUD+0.42%GBPTRY+0.41%CHFNOK+0.39%EURCHF+0.36%GBPCHF+0.36%GBPHKD+0.32%SGDJPY+0.32%CHFSEK+0.31%NZDSGD-0.29%GBPMXN-0.28%EURHKD-0.26%USDDKK+0.25%USDSGD+0.24%EURPLN+0.24%NOKJPY-0.23%EURCNH-0.17%GBPCAD-0.16%USDILS+0.16%CHFSGD-0.16%EURCAD-0.15%USDTRY+0.11%EURUSD-0.08%GBPSGD-0.07%GBPUSD-0.07%PLNJPY+0.07%AUDCHF-0.07%NZDMXN-0.07%AUDNOK+0.06%USDCAD-0.06%USDCNH+0.06%USDCOP-0.04%EURCZK-0.02%EURGBP+0.02%EURSGD-0.01%USDHKD0.00%EURDKK0.00%GAGUSD-4.64%XAGUSD-4.64%XPTUSD-4.57%HG1-4.04%USOIL+3.43%UKOIL+3.26%COFFEE-2.23%XAUUSD-1.35%GAUUSD-1.34%SUGAR+0.65%XNGUSD-0.57%COTTON+0.32%BTCUSD-1.62%ETHUSD-1.43%USDTUSD-0.03%XRPUSD-2.04%SOLUSD-1.76%TRXUSDT+0.12%ZECUSDT-2.70%DOGEUSD-1.89%XMRUSDT-1.95%LINKUSD-1.00%XLMUSD-1.69%BCHUSDT-4.03%LTCUSD-2.05%UNIUSD-3.20%TONUSD+24.88%HBARUSDT-2.15%SUIUSD-2.13%TAOUSDT-3.31%AAVEUSD-2.63%DOTUSDT-2.36%ICPUSDT-1.44%ONDOUSDT-2.70%WLDUSDT-1.71%ATOMUSDT-2.97%ARBUSDT-0.78%JUPUSDT-3.39%INJUSDT-3.40%STXUSDT-3.80%FETUSDT-3.12%TIAUSDT-1.13%PYTHUSDT-1.61%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-3.91%GRTUSDT-4.03%OPUSDT-1.99%POLUSDT-6.46%IOTAUSDT-4.02%AXSUSDT-2.57%FARTCOINUSDT-4.23%EOSUSDT-0.31%DYDXUSDT-0.53%ORDIUSDT-0.40%GALAUSDT-4.21%NOTUSDT-0.68%RONINUSDT-1.67%NVDA-1.38%AAPL+0.39%GOOGL-2.28%MSFT-0.70%AMZN-0.68%TSM-0.83%SPCX-3.86%AVGO-1.13%META-0.31%TSLA-2.02%SKHY+7.05%MU-2.75%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.71%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-2.36%0005.HK-0.78%HSBA.L-1.48%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.41%AUDJPY-1.70%CHFJPY-1.62%NZDCAD-1.32%EURJPY-1.26%NZDUSD-1.26%GBPJPY-1.25%EURNZD+1.20%USDJPY-1.18%GBPNZD+1.17%CADJPY-1.10%USDZAR+0.84%NZDCHF-0.82%USDNOK+0.79%AUDNZD+0.74%USDSEK+0.70%AUDCAD-0.62%USDTHB+0.61%EURZAR+0.60%EURNOK+0.54%GBPZAR+0.54%AUDUSD-0.51%CADCHF+0.50%USDPLN+0.49%AUDSGD-0.48%USDMXN+0.48%AUDDKK-0.47%EURSEK+0.46%USDCHF+0.46%EURAUD+0.45%GBPAUD+0.42%GBPTRY+0.41%CHFNOK+0.39%EURCHF+0.36%GBPCHF+0.36%GBPHKD+0.32%SGDJPY+0.32%CHFSEK+0.31%NZDSGD-0.29%GBPMXN-0.28%EURHKD-0.26%USDDKK+0.25%USDSGD+0.24%EURPLN+0.24%NOKJPY-0.23%EURCNH-0.17%GBPCAD-0.16%USDILS+0.16%CHFSGD-0.16%EURCAD-0.15%USDTRY+0.11%EURUSD-0.08%GBPSGD-0.07%GBPUSD-0.07%PLNJPY+0.07%AUDCHF-0.07%NZDMXN-0.07%AUDNOK+0.06%USDCAD-0.06%USDCNH+0.06%USDCOP-0.04%EURCZK-0.02%EURGBP+0.02%EURSGD-0.01%USDHKD0.00%EURDKK0.00%GAGUSD-4.64%XAGUSD-4.64%XPTUSD-4.57%HG1-4.04%USOIL+3.43%UKOIL+3.26%COFFEE-2.23%XAUUSD-1.35%GAUUSD-1.34%SUGAR+0.65%XNGUSD-0.57%COTTON+0.32%BTCUSD-1.62%ETHUSD-1.43%USDTUSD-0.03%XRPUSD-2.04%SOLUSD-1.76%TRXUSDT+0.12%ZECUSDT-2.70%DOGEUSD-1.89%XMRUSDT-1.95%LINKUSD-1.00%XLMUSD-1.69%BCHUSDT-4.03%LTCUSD-2.05%UNIUSD-3.20%TONUSD+24.88%HBARUSDT-2.15%SUIUSD-2.13%TAOUSDT-3.31%AAVEUSD-2.63%DOTUSDT-2.36%ICPUSDT-1.44%ONDOUSDT-2.70%WLDUSDT-1.71%ATOMUSDT-2.97%ARBUSDT-0.78%JUPUSDT-3.39%INJUSDT-3.40%STXUSDT-3.80%FETUSDT-3.12%TIAUSDT-1.13%PYTHUSDT-1.61%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-3.91%GRTUSDT-4.03%OPUSDT-1.99%POLUSDT-6.46%IOTAUSDT-4.02%AXSUSDT-2.57%FARTCOINUSDT-4.23%EOSUSDT-0.31%DYDXUSDT-0.53%ORDIUSDT-0.40%GALAUSDT-4.21%NOTUSDT-0.68%RONINUSDT-1.67%
CP

Catalyst Pharmaceuticals, Inc. (CPRX)

NASDAQ • Healthcare

$31.49
+$0 (+0.0%)
Market closed

Last close at July 21, 2026 at 20:00 UTC

Open$31.49
Day Range$31.49 - $31.49
Avg. Volume (3M)0
Market Cap$3.8B
P/E Ratio17.5
52 Week Range
$19.05$32.56

Metrics Over Time

Where the Money Goes

Q1 2026
Revenueeverything earned$149.3M100%
Gross Profitminus cost of goods$125.2M84%
Operating Incomeminus R&D and overhead$73.2M49%
Net Incomeminus taxes and the rest$63.7M43%

In plain terms: out of every $100 in revenue, Catalyst Pharmaceuticals, Inc. keeps $43 as net profit.

Fundamentals & Financials

Revenue (TTM)
$596.9M
Net Income (TTM)
$221.3M
EPS (TTM)
$1.8
ROA (TTM)
19.29%
Current Ratio
7.1

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-15.7%Q4 2025$0.43
0.0%Q1 2026$0.42
-18.8%Q2 2026$0.52

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q2 2026
Miss -18.8%

Catalyst Pharmaceuticals’ adjusted EPS of $0.52 trailed the $0.64 estimate by 18.8% and rose 10.6% from $0.47 a year ago, while revenue of $149.4 million was in line with the $149.5 million consensus, -0.1%, in the fiscal first quarter of 2026 reported on May 11. Revenue increased 5.6% to about $149.4 million from $141.4 million a year earlier, with gross margin near 83.8% and operating margin around 49.0% as the company kept profitability high. Net income climbed 12.3% to about $63.7 million from $56.7 million a year ago, operating cash flow came in at about $59.6 million, and Catalyst repurchased roughly $14.6 million of stock. For the next period, consensus calls for adjusted EPS of $0.48 on revenue of $155.8 million.

View full earnings history

About Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a commercial-stage biotechnology company that discovers, develops, and markets therapies for rare, severe, and chronic neuromuscular and neurological disorders in the United States. The company generated $589.0 million in revenue in FY2025 from a business centered on approved LEMS treatments and follow-on development.

Name
Catalyst Pharmaceuticals, Inc.
CEO
Richard John Daly
Website
www.catalystpharma.com
Industry
Healthcare
Year Founded
2002
Employees
182

Today's Snapshot

AI-generated

Yesterday CPRX finished level at 31.49.

vs S&P 500 Today

Moderate Outperformance

+0.48%

Updated: September 10, 2026 at 12:30 UTC

Technical Indicators

5 Buy1 Neutral2 Sell
CPRX shows a clear bullish structure with the market trading above its short-, medium- and long-term moving averages and a very strong ADX that signals a powerful trend. Momentum readings are extended and near overbought levels even as the MACD remains mildly constructive, while OBV confirms accumulation and ATR is very low, implying tight, steady advances rather than volatile spikes. The classic pivot aligns with the current price and has not yet been violated. Technical takeaway: Strong Buy — trend strength and volume profile support the bullish bias.
All signals
  • EMA (5 indicators)$25.72 - $31.48
    Buy
  • RSI (14)70.17
    Sell
  • Stochastic %K (14, 3, 3)85.71
    Sell
  • MACD Level (12, 26)0.12
    Neutral

Peers & Related Assets

EXELExelixis, Inc.
$58.33+1.1%
MDGLMadrigal Pharmaceuticals, Inc.
$546.66+2.3%
AXSMAxsome Therapeutics, Inc.
$210.63+1.4%
VKTXViking Therapeutics, Inc.
$32.7-2.9%
AMLXAmylyx Pharmaceuticals, Inc.
$32.4-4.4%
VSTMVerastem, Inc.
$7.94-1.7%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.